Abstract: The present invention relates indenoazanaphthalenes, particularly for use in electronic devices. The invention further relates to a method for producing the indenoazanaphthalenes according to the invention, and to electronic devices comprising the same.

Abstract: The present invention relates to a formulation containing at least one organic functional material and a mixture of three different organic solvents, a first organic solvent A, a second organic solvent B and a third organic solvent C, characterized in that the first organic solvent A has a boiling point in the range from 250 to 350° C. and a viscosity of ?10 mPas, the second organic solvent B has a boiling point in the range from 200 to 350° C. and a viscosity in the range from 2 to 5 mPas and the third organic solvent C has a boiling point in the range from 100 to 300° C. and a viscosity of ?3 mPas, the solubility of the at least one organic functional material in the second organic solvent B is ?5 g/l, and the boiling point of the first organic solvent A is at least 10° C. higher than the boiling point of the second organic solvent B, to the use of this formulation for the preparation of electronic devices as well as to electronic devices prepared by using these formulations.

Abstract: The present invention relates to a formulation containing at least one organic functional material and at least three different organic solvents, selected from at least two different organic solvents A and at least one organic solvent B, wherein at least one organic solvent A has a boiling point in the range from 250 to 350° C. and a viscosity of ?15 mPas, the at least one organic solvent B has a boiling point in the range from 200 to 350° C. and a viscosity of ?10 mPas, and the solubility of the at least one organic functional material in the second organic solvent B is ?5 g/l; as well as to electroluminescent devices prepared by using these formulations.

Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.

Abstract: The present invention relates to a method for forming an organic element of an electronic device having at least two different pixel types including a first pixel type (pixel A) and a second pixel type (pixel B), —wherein at least one layer of pixel A is deposited by applying an ink A containing at least one organic functional material A and at least one solvent A by a printing process, —wherein at least one layer of pixel B is deposited by applying an ink B containing at least one organic functional material B and at least one solvent B by a printing process, —wherein at least one organic functional material A and at least one organic functional material B are different, and —wherein at least one solvent A and at least one solvent B are different, characterized in that both inks, ink A and ink B, in addition contain at least one common solvent S, and characterized in that the boiling point of solvent A and the boiling point of solvent B is at least 10° C. lower than the boiling point of the common solvent S.

Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.

Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in Claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.

Abstract: The present invention relates to a formulation containing at least one organic functional material and at least three different organic solvents, selected from at least two different organic solvents A and at least one organic solvent B, wherein at least one organic solvent A has a boiling point in the range from 250 to 350° C. and a viscosity of ?15 mPas, the at least one organic solvent B has a boiling point in the range from 200 to 350° C. and a viscosity of ?10 mPas, and the solubility of the at least one organic functional material in the second organic solvent B is ?5 g/l; as well as to electroluminescent devices prepared by using these formulations.

Abstract: The present application concerns silafluorene derivatives according to a specific formula. The silafluorene derivatives can be employed in electronic devices. Furthermore, the present application concerns methods for preparation of the silafluorene derivatives, and electronic devices comprising the silafluorene derivatives.

Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.

Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in Claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.

Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in Claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.

Abstract: The present invention describes spirobifluorene derivatives substituted by pyridine and/or pyrimidine groups, especially for use in electronic devices. The invention further relates to a process for preparing the compounds of the invention and to electronic devices comprising these.

Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in Claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.

Abstract: The present invention relates to tetrahydro-tetrazolo[1,5-a]pyrazine compounds of formula (I), wherein R1 denotes —R3, —CH2—R3 or —CO—R3; R2 denotes Ar2, Hetar2 or C3-7-cycloalkyl; and R3 denotes Ar3, Hetar3 or C3-7-cycloalkyl. These compounds are useful for inhibiting the retinoid-related orphan receptor ? (ROR ?, ROR-gamma) and for the prevention and/or treatment of medical conditions affected by ROR ? activity such as rheumatoid arthritis, multiple sclerosis, psoriasis, ulcerative colitis, asthma, autoimmune hepatitis or type 1 and type 2 diabetes.

Abstract: The present invention relates to tetrahydro-tetrazolo[1,5-a]pyrazine compounds of formula (I), wherein R1 denotes —R3, —CH2—R3 or —CO—R3; R2 denotes Ar2, Hetar2 or C3-7-cycloalkyl; and R3 denotes Ar3, Hetar3 or C3-7-cycloalkyl. These compounds are useful for inhibiting the retinoid-related orphan receptor ? (ROR ?, ROR-gamma) and for the prevention and/or treatment of medical conditions affected by ROR ? activity such as rheumatoid arthritis, multiple sclerosis, psoriasis, ulcerative colitis, asthma, autoimmune hepatitis or type 1 and type 2 diabetes.

Abstract: Compounds of the formula I in which R, R1, X and Y have the meanings indicated in Claim 1, are inhibitors of TBK1 and IKK? and can be employed, inter alia, for the treatment of cancer and inflammatory diseases.

Abstract: 1H-Pyrrolo[2,3-b]pyridine compounds are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.

Abstract: The present invention relates to compounds of the formula I and in particular medicaments comprising at least one compound of the formula I for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which DDR2 is involved, in particular for use in the treatment and/or prophylaxis of osteoarthritis, hepatocirrhosis, traumatic cartilage injuries, pain, allodynia or hyperalgesia.

Abstract: Compounds of the formula (I), in which R1, R2, R2a and R3 have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumors.